AMPE 3.49 Ampio Pharmaceutical $AMPE Hit a 52 week low of 3.19 Closing the day 10:45 at 3.49 +0.22 +6.73% With a day low of 3.19 and a total volume of 261,704.
AMPE Recent Posts: http://investorshangout.com/Ampio-Pharmaceutical-AMPE-53310/
AMPE Ampio Pharmaceutical Recent Headline News
Ampio off premarket on expansion of data analysis in STRUT trial
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 8:05AM CST
AMPE: 3.50 (+0.23)
Ampio updates status of clinical trials and manufacturing facility
PR Newswire - Wed Nov 12, 7:00AM CST
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced an update on its ongoing clinical trials.
AMPE: 3.50 (+0.23)
Technical Report on Pharma Stocks - Auxilium Pharma, Perrigo, Endo Intl., Depomed, and Ampio Pharma
PR Newswire - Fri Oct 24, 7:45AM CDT
Investor-Edge has initiated coverage on the following equities: Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Perrigo Company PLC (NYSE: PRGO), Endo International PLC (NASDAQ: ENDP), Depomed Inc. (NASDAQ: DEPO), and Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, October 23, 2014, the NASDAQ Composite ended at 4,452.79, up 1.60%, the Dow Jones Industrial Average advanced 1.32%, to finish the day at 16,677.90, and the S&P 500 closed at 1,950.82, up 1.23%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 744.13, up 1.75%, with the index also advancing 3.88% in the previous three trading sessions. Register for your complimentary reports on these five stocks at:
ENDP: 67.93 (+0.04), PRGO: 155.80 (+0.93), AUXL: 32.53 (+0.01), DEPO: 14.74 (+0.09), AMPE: 3.50 (+0.23)
Anti-Inflammatory Peptides Competitor Analysis Report 2014
M2 - Wed Oct 22, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9jzrgv/competitor) has announced the addition of the "Competitor Analysis: Anti-Inflammatory Peptides" report to their offering. The present Competitive Intelligence Report about peptides therapeutics provides a competitor evaluation in the field of marketed and new molecules for treatment of inflammatory and autoimmune diseases as of September 2014. Anti-Inflammatory peptides under development and on the market are used for treatment of diseases ranging from psoriasis, multiple sclerosis, transplantation and autoimmune diseases.Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently marketed and active projects in research and development of anti-inflammatory peptides. In addition, the report lists company-specific R&D pipelines of anti-inflammatory peptides. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage Key Topics Covered: 1. 2013 Sales of Major Anti-Inflammatory Peptides 2. Cardiovascular Diseases 3. Dermatological Diseases 4. Gastrointestinal Diseases 5. Neurological Diseases 6. Ophthalmological & Otorhino Diseases 7. Pulmonary & Respiratory Diseases 8. Renal Diseases 9. Rheumatological & Autoimmune Diseases 10. Transplantation 11. Not-Specified Inflammatory & Autoimmune Diseases 12. Corporate Anti-Inflammatory Peptide R&D Pipelines Companies Mentioned - 13Therapeutics - Abbvie - Ampio Pharmaceuticals - Araim Pharmaceuticals - Cognosci - Compugen - Dermadis - Digna Biotech - F4 Pharma - FirstString Research - Immunotech Developments - Kineta - Merck Serono - Momenta Pharmaceuticals - Mylan Pharmaceuticals - NeuroVive Pharmaceutical - Novaliq - Novartis (& Sandoz) - Oryn Pharmaceuticals - Polyphor - Protagonist Therapeutics - Proxima Concepts - Questcor Pharmaceuticals - Rogne Bioscience - Santen - Seagarden - Synthon - Teva Pharmaceutical Industries - To-BBB - XTL Biopharmaceuticals For more information visit http://www.researchandmarkets.com/research/9jzrgv/competitor
QCOR: 93.60 (+1.52), MRK: 59.89 (+0.58), CGEN: 6.80 (-0.03), TEVA: 58.31 (-0.13), AMPE: 3.50 (+0.23), MNTA: 10.92 (+0.21), NVS: 94.39 (+1.73)
Will Ampio (AMPE) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 9:01AM CDT
Will Ampio (AMPE) Continue to Surge Higher?
AMPE: 3.50 (+0.23)
Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences
PR Newswire - Mon Oct 20, 7:00AM CDT
Luoxis Diagnostics, Inc., a subsidiary of Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), today announced that its academic collaborators will present several peer-reviewed posters highlighting the clinical and research potential for its novel RedoxSYS Diagnostic System, a first-in-class platform that measures oxidation-reduction potential (ORP) in the body in response to injury or illness. A poster demonstrating the clinical value of ORP as a clinical marker will be presented by Christopher V. Fanale, MD of Swedish Medical Center at the International Stroke Conference 2015, February 11-13, in Nashville, Tennessee. Three additional posters showcasing RedoxSYS' broad potential as a global, homeostatic measurement of oxidative stress will be presented at 21st annual meeting of The Society for Free Radical Biology and Medicine (SFBRM) November 19-23, 2014 in Seattle, Washington.
AMPE: 3.50 (+0.23)
Ironwood/Actavis Move Linzess into Phase II Study for OIC - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 3:40PM CDT
Ironwood Pharmaceuticals, Inc. (IRWD) announced the commencement of a phase II study on Linzess for the treatment of adults with opioid-induced constipation.
ACT: 244.40 (+3.78), IRWD: 13.70 (-0.05), AZN: 74.80 (+0.54), AMPE: 3.50 (+0.23)
ChemoCentryx, Inc. (CCXI) in Focus: Stock Rises 9.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 8:32AM CDT
ChemoCentryx, Inc. (CCXI) was a big mover last session, as the company saw its shares rise nearly 10% on the day.
CCXI: 5.23 (+0.10), AMPE: 3.50 (+0.23), CEMP: 14.55 (+0.38), ENTA: 44.37 (+1.06)
Tetraphase (TTPH) Crumbles: Stock Tanks by 15% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 7:55AM CDT
Tetraphase has been witnessing a flat trend in its current year earnings estimate and its share price has been falling for past 24 hours
TTPH: 24.06 (-0.04), AMPE: 3.50 (+0.23), CEMP: 14.55 (+0.38), ENTA: 44.37 (+1.06)
Ohr Pharmaceutical's OHR-102 to Enter Phase III in 1H15 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 6:00PM CDT
Ohr Pharmaceutical, Inc.'s (OHRP) OHR-102 will enter phase III studies with the primary endpoint being improvement in visual acuity at 9 months.
AMPE: 3.50 (+0.23), OHRP: 7.25 (-0.02), REGN: 399.89 (-1.22)
Ampio Announces Results of the Open Label Portion of the Multiple Intra-articular Injections (MI) Study of Ampion(TM) in Patients with Osteoarthritis of the Knee at Week Twelve of the Trial
PR Newswire - Thu Oct 16, 3:02PM CDT
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced updates for the STRUT and STRIDE multiple injection studies that are proceeding simultaneously.
AMPE: 3.50 (+0.23)
Corcept Therapeutics (CORT) Jumps: Stock Rises 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 8:32AM CDT
Corcept Therapeutics Incorporated (CORT) was a big mover last session, as the company saw its shares rise more than 6% on the day.
CANF: 2.70 (+0.16), AMPE: 3.50 (+0.23), CEMP: 14.55 (+0.38), CORT: 3.08 (+0.02)
ARIAD's Iclusig Gains Positive Recommendation from PRAC - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 4:05PM CDT
Ariad Pharmaceuticals Inc. (ARIA) announced that the PRAC issued a positive feedback in favor of Iclusig and that it can be continued to be used in Europe.
AMPE: 3.50 (+0.23), BMY: 58.02 (-0.59), ARIA: 6.49 (+0.02), NVS: 94.39 (+1.73)
Esperion Therapeutics Slumps: ESPR Falls 6.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 7:48AM CDT
Esperion Therapeutics has been witnessing a flat trend in its current year earnings estimate and its share price has been falling for past 24 hours
ESPR: 30.36 (+0.69), AMPE: 3.50 (+0.23), CEMP: 14.55 (+0.38), CORT: 3.08 (+0.02)
Genocea Up on Positive GEN-003 Data for Genital Herpes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 09, 1:57PM CDT
Genocea Biosciences, Inc. (GNCA) announced data from a phase I/IIa study on its T cell-enabled immunotherapy candidate, GEN-003.
LCI: 50.25 (+0.52), NVAX: 5.29 (+0.05), AMPE: 3.50 (+0.23), GNCA: 9.00 (unch)
Karyopharm Therapeutics, Inc. (KPTI) Surges: Stock Adds 10.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 8:11AM CDT
Karyopharm Therapeutics, Inc. (KPTI) was a big mover last session, as the company saw its shares rise nearly 11% on the day.
LCI: 50.25 (+0.52), ENDP: 67.93 (+0.04), AMPE: 3.50 (+0.23), KPTI: 41.89 (-0.52)
Ampio Pharmaceuticals Announces Webcast for Annual Shareholder Meeting
PR Newswire - Mon Sep 15, 1:00PM CDT
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) a clinical trial stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options, today announced that its September 20, 2014 annual meeting of shareholders will be shared live through a webcast. This webcast will provide audio throughout supplemented by video of the slides and videos supporting presentations by management as well as the direct reports of clinical investigators that have participated in past (single injection) and ongoing (multiple injection) AmpionTM clinical trials.
AMPE: 3.50 (+0.23)
Health Care Sector Stocks Technical Review - Ampio Pharma, InterMune, Biogen Idec, Hologic, and CareFusion Corp.
PR Newswire - Mon Sep 15, 7:40AM CDT
On Friday, September 12, 2014, the NASDAQ Composite ended at 4,567.60, down 0.53%, the Dow Jones Industrial Average finished the day 0.36% lower at 16,987.51, and the S&P 500 closed at 1,985.54, down 0.60%. The losses were broad based as all the ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 736.69, down 0.69%, while the index has advanced 2.86% in the last one month. Investor-Edge has initiated coverage on the following equities: Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE), InterMune Inc. (NASDAQ: ITMN), Biogen Idec Inc. (NASDAQ: BIIB), Hologic Inc. (NASDAQ: HOLX), and CareFusion Corporation (NYSE: CFN). Free research on these five companies can be accessed at:
BIIB: 321.20 (+0.18), CFN: 57.59 (+0.03), ITMN: 73.89 (-0.02), AMPE: 3.50 (+0.23), HOLX: 26.67 (+0.12)
Another Mixed Stock Market Day but Indexes May Go Higher Friday
at The Street - Thu Sep 11, 4:24PM CDT
The stock indexes shed most of their losses Thursday as the indexes position themselves for another move higher.
SPY: 204.68 (+0.72), INVN: 14.29 (+0.03), AMPE: 3.50 (+0.23), AUY: 3.74 (-0.03)
U.S. Stocks Stage Unimpressive Rebound as Apple Leads the Way
at The Street - Wed Sep 10, 4:42PM CDT
The major stock indexes rebounded on Wednesday but will it continue Thursday?
SPY: 204.68 (+0.72), AMPE: 3.50 (+0.23), AUY: 3.74 (-0.03), AAPL: 113.20 (+1.95)
AMPE Recent Posts: http://investorshangout.com/Ampio-Pharmaceutical-AMPE-53310/
AMPE Ampio Pharmaceutical Recent Headline News
Ampio off premarket on expansion of data analysis in STRUT trial
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 8:05AM CST
AMPE: 3.50 (+0.23)
Ampio updates status of clinical trials and manufacturing facility
PR Newswire - Wed Nov 12, 7:00AM CST
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced an update on its ongoing clinical trials.
AMPE: 3.50 (+0.23)
Technical Report on Pharma Stocks - Auxilium Pharma, Perrigo, Endo Intl., Depomed, and Ampio Pharma
PR Newswire - Fri Oct 24, 7:45AM CDT
Investor-Edge has initiated coverage on the following equities: Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL), Perrigo Company PLC (NYSE: PRGO), Endo International PLC (NASDAQ: ENDP), Depomed Inc. (NASDAQ: DEPO), and Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, October 23, 2014, the NASDAQ Composite ended at 4,452.79, up 1.60%, the Dow Jones Industrial Average advanced 1.32%, to finish the day at 16,677.90, and the S&P 500 closed at 1,950.82, up 1.23%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 744.13, up 1.75%, with the index also advancing 3.88% in the previous three trading sessions. Register for your complimentary reports on these five stocks at:
ENDP: 67.93 (+0.04), PRGO: 155.80 (+0.93), AUXL: 32.53 (+0.01), DEPO: 14.74 (+0.09), AMPE: 3.50 (+0.23)
Anti-Inflammatory Peptides Competitor Analysis Report 2014
M2 - Wed Oct 22, 5:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9jzrgv/competitor) has announced the addition of the "Competitor Analysis: Anti-Inflammatory Peptides" report to their offering. The present Competitive Intelligence Report about peptides therapeutics provides a competitor evaluation in the field of marketed and new molecules for treatment of inflammatory and autoimmune diseases as of September 2014. Anti-Inflammatory peptides under development and on the market are used for treatment of diseases ranging from psoriasis, multiple sclerosis, transplantation and autoimmune diseases.Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently marketed and active projects in research and development of anti-inflammatory peptides. In addition, the report lists company-specific R&D pipelines of anti-inflammatory peptides. Competitor projects are listed in a tabular format providing information on: - Drug Codes - Target / Mechanism of Action - Class of Compound - Company - Product Category - Indication - R&D Stage Key Topics Covered: 1. 2013 Sales of Major Anti-Inflammatory Peptides 2. Cardiovascular Diseases 3. Dermatological Diseases 4. Gastrointestinal Diseases 5. Neurological Diseases 6. Ophthalmological & Otorhino Diseases 7. Pulmonary & Respiratory Diseases 8. Renal Diseases 9. Rheumatological & Autoimmune Diseases 10. Transplantation 11. Not-Specified Inflammatory & Autoimmune Diseases 12. Corporate Anti-Inflammatory Peptide R&D Pipelines Companies Mentioned - 13Therapeutics - Abbvie - Ampio Pharmaceuticals - Araim Pharmaceuticals - Cognosci - Compugen - Dermadis - Digna Biotech - F4 Pharma - FirstString Research - Immunotech Developments - Kineta - Merck Serono - Momenta Pharmaceuticals - Mylan Pharmaceuticals - NeuroVive Pharmaceutical - Novaliq - Novartis (& Sandoz) - Oryn Pharmaceuticals - Polyphor - Protagonist Therapeutics - Proxima Concepts - Questcor Pharmaceuticals - Rogne Bioscience - Santen - Seagarden - Synthon - Teva Pharmaceutical Industries - To-BBB - XTL Biopharmaceuticals For more information visit http://www.researchandmarkets.com/research/9jzrgv/competitor
QCOR: 93.60 (+1.52), MRK: 59.89 (+0.58), CGEN: 6.80 (-0.03), TEVA: 58.31 (-0.13), AMPE: 3.50 (+0.23), MNTA: 10.92 (+0.21), NVS: 94.39 (+1.73)
Will Ampio (AMPE) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 9:01AM CDT
Will Ampio (AMPE) Continue to Surge Higher?
AMPE: 3.50 (+0.23)
Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences
PR Newswire - Mon Oct 20, 7:00AM CDT
Luoxis Diagnostics, Inc., a subsidiary of Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), today announced that its academic collaborators will present several peer-reviewed posters highlighting the clinical and research potential for its novel RedoxSYS Diagnostic System, a first-in-class platform that measures oxidation-reduction potential (ORP) in the body in response to injury or illness. A poster demonstrating the clinical value of ORP as a clinical marker will be presented by Christopher V. Fanale, MD of Swedish Medical Center at the International Stroke Conference 2015, February 11-13, in Nashville, Tennessee. Three additional posters showcasing RedoxSYS' broad potential as a global, homeostatic measurement of oxidative stress will be presented at 21st annual meeting of The Society for Free Radical Biology and Medicine (SFBRM) November 19-23, 2014 in Seattle, Washington.
AMPE: 3.50 (+0.23)
Ironwood/Actavis Move Linzess into Phase II Study for OIC - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 3:40PM CDT
Ironwood Pharmaceuticals, Inc. (IRWD) announced the commencement of a phase II study on Linzess for the treatment of adults with opioid-induced constipation.
ACT: 244.40 (+3.78), IRWD: 13.70 (-0.05), AZN: 74.80 (+0.54), AMPE: 3.50 (+0.23)
ChemoCentryx, Inc. (CCXI) in Focus: Stock Rises 9.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 8:32AM CDT
ChemoCentryx, Inc. (CCXI) was a big mover last session, as the company saw its shares rise nearly 10% on the day.
CCXI: 5.23 (+0.10), AMPE: 3.50 (+0.23), CEMP: 14.55 (+0.38), ENTA: 44.37 (+1.06)
Tetraphase (TTPH) Crumbles: Stock Tanks by 15% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 7:55AM CDT
Tetraphase has been witnessing a flat trend in its current year earnings estimate and its share price has been falling for past 24 hours
TTPH: 24.06 (-0.04), AMPE: 3.50 (+0.23), CEMP: 14.55 (+0.38), ENTA: 44.37 (+1.06)
Ohr Pharmaceutical's OHR-102 to Enter Phase III in 1H15 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 6:00PM CDT
Ohr Pharmaceutical, Inc.'s (OHRP) OHR-102 will enter phase III studies with the primary endpoint being improvement in visual acuity at 9 months.
AMPE: 3.50 (+0.23), OHRP: 7.25 (-0.02), REGN: 399.89 (-1.22)
Ampio Announces Results of the Open Label Portion of the Multiple Intra-articular Injections (MI) Study of Ampion(TM) in Patients with Osteoarthritis of the Knee at Week Twelve of the Trial
PR Newswire - Thu Oct 16, 3:02PM CDT
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced updates for the STRUT and STRIDE multiple injection studies that are proceeding simultaneously.
AMPE: 3.50 (+0.23)
Corcept Therapeutics (CORT) Jumps: Stock Rises 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 8:32AM CDT
Corcept Therapeutics Incorporated (CORT) was a big mover last session, as the company saw its shares rise more than 6% on the day.
CANF: 2.70 (+0.16), AMPE: 3.50 (+0.23), CEMP: 14.55 (+0.38), CORT: 3.08 (+0.02)
ARIAD's Iclusig Gains Positive Recommendation from PRAC - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 4:05PM CDT
Ariad Pharmaceuticals Inc. (ARIA) announced that the PRAC issued a positive feedback in favor of Iclusig and that it can be continued to be used in Europe.
AMPE: 3.50 (+0.23), BMY: 58.02 (-0.59), ARIA: 6.49 (+0.02), NVS: 94.39 (+1.73)
Esperion Therapeutics Slumps: ESPR Falls 6.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 7:48AM CDT
Esperion Therapeutics has been witnessing a flat trend in its current year earnings estimate and its share price has been falling for past 24 hours
ESPR: 30.36 (+0.69), AMPE: 3.50 (+0.23), CEMP: 14.55 (+0.38), CORT: 3.08 (+0.02)
Genocea Up on Positive GEN-003 Data for Genital Herpes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 09, 1:57PM CDT
Genocea Biosciences, Inc. (GNCA) announced data from a phase I/IIa study on its T cell-enabled immunotherapy candidate, GEN-003.
LCI: 50.25 (+0.52), NVAX: 5.29 (+0.05), AMPE: 3.50 (+0.23), GNCA: 9.00 (unch)
Karyopharm Therapeutics, Inc. (KPTI) Surges: Stock Adds 10.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 8:11AM CDT
Karyopharm Therapeutics, Inc. (KPTI) was a big mover last session, as the company saw its shares rise nearly 11% on the day.
LCI: 50.25 (+0.52), ENDP: 67.93 (+0.04), AMPE: 3.50 (+0.23), KPTI: 41.89 (-0.52)
Ampio Pharmaceuticals Announces Webcast for Annual Shareholder Meeting
PR Newswire - Mon Sep 15, 1:00PM CDT
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) a clinical trial stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options, today announced that its September 20, 2014 annual meeting of shareholders will be shared live through a webcast. This webcast will provide audio throughout supplemented by video of the slides and videos supporting presentations by management as well as the direct reports of clinical investigators that have participated in past (single injection) and ongoing (multiple injection) AmpionTM clinical trials.
AMPE: 3.50 (+0.23)
Health Care Sector Stocks Technical Review - Ampio Pharma, InterMune, Biogen Idec, Hologic, and CareFusion Corp.
PR Newswire - Mon Sep 15, 7:40AM CDT
On Friday, September 12, 2014, the NASDAQ Composite ended at 4,567.60, down 0.53%, the Dow Jones Industrial Average finished the day 0.36% lower at 16,987.51, and the S&P 500 closed at 1,985.54, down 0.60%. The losses were broad based as all the ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 736.69, down 0.69%, while the index has advanced 2.86% in the last one month. Investor-Edge has initiated coverage on the following equities: Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE), InterMune Inc. (NASDAQ: ITMN), Biogen Idec Inc. (NASDAQ: BIIB), Hologic Inc. (NASDAQ: HOLX), and CareFusion Corporation (NYSE: CFN). Free research on these five companies can be accessed at:
BIIB: 321.20 (+0.18), CFN: 57.59 (+0.03), ITMN: 73.89 (-0.02), AMPE: 3.50 (+0.23), HOLX: 26.67 (+0.12)
Another Mixed Stock Market Day but Indexes May Go Higher Friday
at The Street - Thu Sep 11, 4:24PM CDT
The stock indexes shed most of their losses Thursday as the indexes position themselves for another move higher.
SPY: 204.68 (+0.72), INVN: 14.29 (+0.03), AMPE: 3.50 (+0.23), AUY: 3.74 (-0.03)
U.S. Stocks Stage Unimpressive Rebound as Apple Leads the Way
at The Street - Wed Sep 10, 4:42PM CDT
The major stock indexes rebounded on Wednesday but will it continue Thursday?
SPY: 204.68 (+0.72), AMPE: 3.50 (+0.23), AUY: 3.74 (-0.03), AAPL: 113.20 (+1.95)
